Skip to main content

Table 1 Characteristics of the included studies

From: Recombinant human endostatin combined with chemotherapy for advanced squamous cell lung cancer: a meta-analysis

Studies

Number (C/E)

Age

Sex (F/M)

Regimens

PFS (C/E, months)

Wu F [12]

25/25

37–74

15/35

GNE vs GN

5.72 ± 0.89/6.90 ± 1.15

Song WC [13]

30/30

33–74

26/34

GPE vs GP

Wang ZF [14]

30/34

35–70

3/61

GPE vs GP

7.35 ± 0.52/13.41 ± 1.23

Chen Q [15]

19/21

65–85

GE vs G

3.7/4

Lv Y [16]

10/10

60–83

4/16

DPE vs DP

Yang L [17]

37/35

13/59

GPE vs GP

5.5/7.0

Zheng X [18]

40/40

60–69

29/51

GPE vs GP

6.12 ± 1.78/9.51 ± 2.15

Wang W [19]

50/50

51–56

40/60

PPE vs PP

6.3/8.4

Xun Yu [20]

14/12

46.78–65.88

GCE vs GC

5.1 ± 0.6/8.2 ± 1.3

Shi HL [21]

6/3

37–74

NPE vs NP

Yang L [22]

10/24

33–78

VPE vs VP

Wang QZ [23]

29/29

12/46

DPE vs DP

4.97/7.17

Zhang YY [24]

26/27

53–54

6/53

GPE vs GP

6.5/8.3

Hong S [25]

52/98

32–80

14/136

GPE vs GP

  1. Note: The dashes represent no data;
  2. C the control group, E the experimental group, F female, M male; GNE gemcitabine + nedaplatin + Endostar, GN gemcitabine + nedaplatin, GPE gemcitabine + cisplatin + Endostar, GP gemcitabine + cisplatin, GE gemcitabine + Endostar, G gemcitabine, DPE docetaxel + cisplatin + Endostar, DP docetaxel + cisplatin, PPE paclitaxel + cisplatin + Endostar, PP paclitaxel + cisplatin, GCE gemcitabine + carboplatin + Endostar, GC gemcitabine + carboplatin, NPE norvincristine + cisplatin + Endostar, NP norvincristine + cisplatin, VPE vinorelbine + cisplatin + Endostar, VP vinorelbine + cisplatin